FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
Condition(s):Systemic Lupus ErythematosusLast Updated:March 13, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Systemic Lupus ErythematosusLast Updated:March 13, 2024Recruiting
Condition(s):Advanced Solid TumorLast Updated:February 7, 2024Recruiting
Condition(s):Relapsed/Refractory B-Cell LymphomaLast Updated:March 7, 2024Recruiting
Condition(s):Diffuse Large B Cell Lymphoma; Transformed Indolent Non-Hodgkin’s Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone LymphomaLast Updated:July 6, 2023Withdrawn
Condition(s):Non Small Cell Lung Cancer; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Head and Neck Cancer; GastroEsophageal CancerLast Updated:September 21, 2023Terminated
Condition(s):Multiple Myeloma; MyelomaLast Updated:March 15, 2024Recruiting
Condition(s):Solid Tumor, AdultLast Updated:September 21, 2023Terminated
Condition(s):Lymphoma, B-Cell; Chronic Lymphocytic Leukemia; Precursor B-Cell Acute Lymphoblastic LeukemiaLast Updated:November 2, 2023Recruiting
Condition(s):Acute Myeloid Leukemia; AML, Adult; Multiple Myeloma; MyelomaLast Updated:September 21, 2023Terminated
Condition(s):Solid Tumor, AdultLast Updated:September 21, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.